Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours (NETs): An international double-blind, placebo-controlled randomized phase II trial

Affiliation auteursAffiliation ok
TitreLanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours (NETs): An international double-blind, placebo-controlled randomized phase II trial
Type de publicationJournal Article
Year of Publication2020
AuteursLepage C., Phelip J.M, Lievre A., Le Malicot K., Tougeron D., Dahan L., Toumpanakis C., Di Fiore F., C. Bohas L, Borbath I., Coriat R., Caulet M., Guimbaud R., Petorin C., Legoux J.L, Scoazec J-Y., Michel P., Cadiot G., Smith D., Walter T.
JournalANNALS OF ONCOLOGY
Volume31
PaginationS774
Date PublishedSEP
Type of ArticleMeeting Abstract
ISSN0923-7534
DOI10.1016/j.annonc.2020.08.1376